Trends in Darunavir Resistance-Associated Mutations and Phenotypic Resistance in Commercially Tested United States Clinical Samples Between 2006 and 2012-Reference-Cited by-同舟云学术

Trends in Darunavir Resistance-Associated Mutations and Phenotypic Resistance in Commercially Tested United States Clinical Samples Between 2006 and 2012

Published:2015-06 Issue:6 Volume:31 Page:628-635
ISSN:0889-2229
Container-title:AIDS Research and Human Retroviruses
language:en
Short-container-title:AIDS Research and Human Retroviruses

Author:

Lathouwers Erkki¹,Gupta Soumi²,Haddad Mojgan³,Paquet Agnes³,de Meyer Sandra¹,Baugh Bryan²

Affiliation:

1. Janssen Infectious Diseases BVBA, Beerse, Belgium.

2. Janssen Therapeutics, Titusville, New Jersey.

3. Monogram Biosciences, South San Francisco, California.

Publisher

Mary Ann Liebert Inc

Subject

Infectious Diseases,Virology,Immunology

Link

http://www.liebertpub.com/doi/pdf/10.1089/aid.2014.0020

Reference26 articles.

1. Antiretroviral Treatment of Adult HIV Infection

2. Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis

3. Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patients

4. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pooled resistance analyses of darunavir once-daily regimens and formulations across 10 clinical studies of treatment-naïve and treatment-experienced patients with human immunodeficiency virus-1 infection;HIV Research & Clinical Practice;2020-05-03

2. Trends in HIV-1 Drug Resistance Mutations from a U.S. Reference Laboratory from 2006 to 2017;AIDS Research and Human Retroviruses;2019-08

3. Effectiveness and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced patients with advanced HIV infection: a preliminary 24 week analysis (RIDAR study);BMC Infectious Diseases;2019-02-28

4. Impact of Splitting or Crushing on the Relative Bioavailability of the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single‐Tablet Regimen;Clinical Pharmacology in Drug Development;2018-12-03

5. Prevalence of Darunavir Resistance in the United States from 2010 to 2017;AIDS Research and Human Retroviruses;2018-12